SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Hitchings, AW; Kumar, M; Jordan, S; Nargund, V; Martin, J; Berney, DM (2004) Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb. British Journal of Cancer, 91 (3). pp. 552-557. ISSN 0007-0920 https://doi.org/10.1038/sj.bjc.6601954
SGUL Authors: Hitchings, Andrew William

[img]
Preview
["document_typename_application/pdf; charset=binary" not defined] Published Version
Download (161kB) | Preview

Abstract

Currently available prognostic tools appear unable to adequately predict recurrence and progression in non muscle-invasive bladder carcinomas. We aimed to assess the prognostic value of immunohistochemical evaluation of the cell cycle markers p53, p16 and pRb. Paraffin blocks were obtained from 78 cases of pTa and pT1 transitional cell carcinomas, for which long-term follow-up was available. Representative sections were stained using antibodies against p53, p16 and pRb. Altered marker expression was found in 45, 17 and 30% of cases, respectively. Concurrent alteration of two or three markers occurred in 19% of cases, and was significantly associated with grade and stage. In univariate survival analysis, the concurrent alteration of any two markers was significantly associated with progression. The greatest risk was produced by alteration of both p53 and p16, which increased the risk of progression by 14.45 times (95% confidence interval (CI) 3.10-67.35). After adjusting for grade and stage, this risk was 7.73 (CI 1.13-52.70). The markers did not generally predict tumour recurrence, except in the 25 pT1 tumours. In these, p16 alteration was associated with a univariate risk of 2.83 (CI 1.01-7.91), and concurrent p53 and p16 alteration with a risk of 9.29 (CI 1.24-69.50). Overall, we conclude that the immunohistochemical evaluation of p53 and p16 may have independent prognostic value for disease progression, and may help guide management decisions in these tumours.

Item Type: Article
Additional Information: ©2004 Cancer Research UK. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
Keywords: Adult, Aged, Aged, 80 and over, Antibodies, Carcinoma, Transitional Cell, Cell Cycle, Cyclin-Dependent Kinase Inhibitor p16, Disease Progression, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Predictive Value of Tests, Prognosis, Retinoblastoma Protein, Retrospective Studies, Tumor Markers, Biological, Tumor Suppressor Protein p53, Urinary Bladder Neoplasms, Oncology & Carcinogenesis, 1112 Oncology And Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: British Journal of Cancer
ISSN: 0007-0920
Language: eng
Dates:
DateEvent
2 August 2004Published
PubMed ID: 15226775
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/107213
Publisher's version: https://doi.org/10.1038/sj.bjc.6601954

Actions (login required)

Edit Item Edit Item